Reference
Lee WA, et al. Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study. BioDrugs : Mar 2022. Available from: URL: http://doi.org/10.1007/s40259-022-00516-y
Rights and permissions
About this article
Cite this article
Risk of aflibercept- and ranibizumab-related thromboembolic events. Reactions Weekly 1897, 12 (2022). https://doi.org/10.1007/s40278-022-11249-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-11249-2